EN DE
Watch SinoMab BioScience Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SinoMab BioScience Ltd (3681) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of SinoMab BioScience Ltd stock HK$0.80, price HK$0.96, that is 16.2% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · ISIN HK0000544194

SB SinoMab BioScience Ltd logo Thin data Nov 10, 2026

SinoMab BioScience Ltd

3681 · HK

Expensive (fair value 16% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +61% vs. a year ago. 
Mixed vs. peers (4/7) 
Fair value HK$0.8000 · Overvalued 
Quality 34/100 
Falling price (downtrend) 
Weak Growth (revenue 3y −57.6 %/yr in HKD) 
Negative free cash flow 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch SinoMab BioScience Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$3.65 HK$0.9500 Fair Value HK$0.8000 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$0.9500 – HK$3.65 · fair‑value band HK$0.6000 – HK$1.00 · the HK$0.9550 price screens above the HK$0.8000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow SinoMab BioScience in your weekly email

Every Wednesday you see whether SinoMab BioScience is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong.

Show moreShow less

Its product pipeline comprises SM03 (Suciraslimab), a first-in-class anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin's lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer's disease and sjogren's syndrome.

It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optical spectrum disorder, and multiple sclerosis, as well as to treat systemic lupus erythematosus.

In addition, the company is developing SM06, a humanised Anti-CD22, that is in preclinical trial to treat systemic lupus erythematosus, rheumatoid arthritis, neuromyelitis optica spectrum disorder, and sjogren's syndrome; and SM09, a humanised Anti-CD22, which is in preclinical trial to treat non-hodgkin's lymphoma and autoimmune diseases.

Further, it develops Anti-CGC antibody, which is in preclinical trial to treat vitiligo and alopecia areata; and Bispecific antibody candidate (bsAb), which is in preclinical trial to treat osteoporosis. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Tai Po, Hong Kong.

Stock analysis

SinoMab BioScience Ltd (3681) currently trades at HK$0.9550, while our estimate is HK$0.8000, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.6000 (bear) to HK$1.00 (bull), the price of HK$0.9550 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

SinoMab BioScience Ltd reported revenue of 0 CNY in FY2025 versus 26.7M CNY in FY2021. Reported net income was −102M CNY in FY2025.

Key figures

Market cap HK$1.3B (≈ $166M) Micro · EPS (TTM) HK$−0.0500 · Return on equity −30.0% · Return on assets (EBIT) −23.5% (5-year average) · Operating margin 831% · Revenue (TTM) HK$5.7M · Revenue growth (YoY) +60.9% · Free cash flow −HK$95.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 55% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −16%, 3681 screens richer than that median.

Fair Value

Bear HK$0.6000 Fair Value HK$0.8000 Bull HK$1.00
Price HK$0.9550 · Downside -16.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 45
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 2
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+48.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−57.6%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,702.6% (2018) → −7,964.2% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

3681 screens overvalued: fair value 16% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare SinoMab BioScience Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 34 · Below median
Fair Value upside −16.2% · Above median
Profitability
Return on assets −11.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 60.9% · Top 25%
Balance sheet
Debt / equity 0.38× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.57× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)81 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs 3681
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs 3681
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs 3681
Genmab A/S GMAB kr 3,448 kr 3,793 +10% vs 3681
argenx SE ARGX $960.04 $908.40 −5% vs 3681
CSL Limited CSL A$202.52 A$185.51 −8% vs 3681
Moderna, Inc MRNA $223.37 $139.99 −37% vs 3681
Revolution Medicines, Inc RVMD $172.29 $88.78 −48% vs 3681
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs 3681
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs 3681

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SinoMab BioScience Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SinoMab BioScience Ltd Fair Value". https://www.fairvalue-calculator.com/stock/3681

Frequently asked questions

Is SinoMab BioScience Ltd (3681) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$0.8000 versus a price of HK$0.9550, about 16% lower (overvalued).
What is the fair value of 3681?
Our estimate for SinoMab BioScience Ltd is HK$0.8000 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.9550.
What is the quality score of 3681?
SinoMab BioScience Ltd has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SinoMab BioScience Ltd (3681)?
Our calculated price target is the estimate of HK$0.8000 (as of Nov 10, 2026). Cautious scenario HK$0.6000, optimistic scenario HK$1.00. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the SinoMab BioScience Ltd stock forecast for 2026?
Our estimate puts fair value at HK$0.8000, about 16% lower versus a price of HK$0.9550 (overvalued). Cautious scenario HK$0.6000, optimistic scenario HK$1.00. The calculation is refreshed regularly with new filings.
What is the revenue of SinoMab BioScience Ltd (3681)?
SinoMab BioScience Ltd reported trailing-twelve-month revenue of about HK$5.7M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of SinoMab BioScience Ltd (3681)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SinoMab BioScience Ltd it is HK$0.8000 per share (as of Nov 10, 2026), against a price of HK$0.9550.
Is SinoMab BioScience Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 3681 trades above its calculated fair value: price HK$0.9550, fair value HK$0.8000, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3681?
No. The price is what the market pays today (HK$0.9550); the fair value is what the company's own numbers justify (HK$0.8000). For SinoMab BioScience Ltd the two are HK$0.1550 per share apart. That gap is exactly why we show both numbers side by side.
How much is SinoMab BioScience Ltd worth?
The market values SinoMab BioScience Ltd at about HK$1.3B (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.9550; our models calculate a fair value of HK$0.8000 per share.
What do the bullish and bearish scenarios say about 3681?
Our models span a range for SinoMab BioScience Ltd: cautious scenario HK$0.6000, base HK$0.8000, optimistic HK$1.00 per share (as of Nov 10, 2026, price HK$0.9550). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SinoMab BioScience Ltd (3681)?
Balance-sheet figures for SinoMab BioScience Ltd (as of Nov 10, 2026): return on equity −30.0%, debt of 0.38 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is 3681 from its 52-week high?
SinoMab BioScience Ltd trades at HK$0.9550, about 55% below its 52-week high of HK$2.13 and at the low of HK$0.9550 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.8000 is for.
Which stocks are comparable to SinoMab BioScience Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SinoMab BioScience Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.9550, calculated fair value HK$0.8000 (−16%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. SinoMab BioScience Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SinoMab BioScience Ltd (3681)?
The closing price on Nov 13, 2026 was HK$0.9550. Our estimate is HK$0.8000, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SinoMab BioScience Ltd right now?
Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of SinoMab BioScience Ltd

How large is the market capitalisation of SinoMab BioScience Ltd (3681)?
The market capitalisation of SinoMab BioScience Ltd is HK$1.3B (≈ $166M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of SinoMab BioScience Ltd (3681)?
Earnings per share at SinoMab BioScience Ltd are HK$−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of SinoMab BioScience Ltd (3681)?
The return on equity (ROE) of SinoMab BioScience Ltd is −30.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SinoMab BioScience Ltd (3681)?
On an EBIT basis the return on assets of SinoMab BioScience Ltd is −23.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SinoMab BioScience Ltd (3681)?
The operating margin of SinoMab BioScience Ltd is 831% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SinoMab BioScience Ltd (3681)?
Revenue at SinoMab BioScience Ltd is growing 60.9% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SinoMab BioScience Ltd (3681) generate?
The free cash flow of SinoMab BioScience Ltd is −HK$95.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SinoMab BioScience Ltd (3681) carry?
The net debt of SinoMab BioScience Ltd is HK$5.0M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch SinoMab BioScience Ltd in the live analysis

One click puts SinoMab BioScience Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.